Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

"Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR and ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A recent study from the University of Hong Kong suggests that a newer type of diabetes drug, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may help protect the kidneys and lungs in people ...

This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of ... this study was sufficiently powered to address the long-term safety of PPIs and assess the ...

Share on Pinterest An SGLT-2 inhibitor drug plus a moderately calorie-restrictive diet may be the best approach for achieving diabetes remission. Image credit: Xvision/Getty Images. About 828 ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...